Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 8 | BMC Cancer

Fig. 8

From: Bifidobacterial recombinant thymidine kinase-ganciclovir gene therapy system induces FasL and TNFR2 mediated antitumor apoptosis in solid tumors

Fig. 8

Survival rate analysis of a wide variety of solid tumor mice models in BF-rTK + GCV treatment. a Three different kinds of human solid tumor models (gastric cancer MKN-45 (GCA), breast cancer MDA-MB-231 (BCA) and liver cancer SSMC-7721 (LCA)) were established by injecting cancer cells (1.0 × 108 cells/ml) subcutaneously. Each positive group contained six nude mice that had BF-rTK + GCV intratumorally injected twice in five days after the xenograft tumor diameter was more than 3.5 mm (BF-rTK + GCV was 1.0 × 106 cell/tumor, n = 6) and GCV (5.0 mg/kg) was given as an intramuscular injection every day during the five days. Each negative control group of six nude mice bearing xenograft tumors were raised without any injections (Ctrl, n = 6). After the second BF-rTK + GCV injection for positive groups, all mice were raised without any treatment. The mice that survived were counted every day. The data at the 1 d, 5 d, 17 d, 19 d, 21 d, 24 d, 27 d, 30 d, 35 d and 37 d postinjection were used to analyze survival rate (*P < 0.05). b On 32 d postinjection, the tumors were isolated from three different groups and the tumor size was compared between the control and treatment groups

Back to article page